SXTC - sxtchina.com Debt to Book Capitalization Ratio

Graphic logo of China SXT Pharmaceuticals, Inc. (SXTC)

This chart illustrates the market value of China SXT Pharmaceuticals (SXTC), which currently stands at 0.04, supported by the modernization of China's traditional medicine production plants and growth in sales through government agencies. China SXT Pharmaceuticals (SXTC) maintains its position in a mature domestic market by raising quality standards, while simultaneously implementing environmental filters and strictly tracking the origin of natural raw materials.

SXTC (China SXT Pharmaceuticals, Inc.) Debt to Book Value history from 07/04/2022 to 10/29/2026
Core merchandise of China SXT Pharmaceuticals, Inc.

To assess the issuer's financial stability, the ratio of total liabilities to equity on the balance sheet is used, which determines the extent to which the financing structure depends on borrowed funds. By analyzing the debt-to-book capitalization metric for China SXT Pharmaceuticals (SXTC) on the GURU.Markets platform, an investor can see how effectively China SXT Pharmaceuticals balances its credit load to expand within the Asian generics sector without the risk of default.

Competitors of China SXT Pharmaceuticals

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio tonixpharma.com (TNXP)|Eupraxia Pharmaceuticals Inc. - Debts to Book Capitalization|Debt to Book Value BioHarvest Sciences, Inc. BHST|Debts to Book Capitalization Invizyne Technologies, Inc. (EXOZ)|ORMP - Debt to Net Assets Ratio|enterabio.com - Debts to Book Capitalization|HYFT (ipatherapeutics.com) - Debts to Net Assets|Debt to Book Capitalization Ratio ABVC BioPharma, Inc. (ABVC)|Debt to Book Value Ratio Cumberland Pharmaceuticals Inc|Debts to Book Capitalization QNTM|Debts to Book Capitalization FibroGen Corporation FGEN|Debt to Book Value Telomir Pharmaceuticals|Rani Therapeutics Holdings - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio SNYR (Synergy CHC Corporation)|Rallybio Corporation (RLYB) - Debts to Net Assets|Debt to Book Value lexariabioscience.com|Debt to Book Value Ratio Pulmatrix Corporation|Pheton Holdings Limited (PTHL) - Debt to Book Value|Debt to Book Capital Aptorum (APM)|Lyra Therapeutics (LYRA) - Debt to Book Value|Debt to Net Assets Ratio IBO (Impact BioMedical, Inc.)|TNF Pharmaceuticals, Inc. (TNFA) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio cbdMD Inc. YCBD|Debts to Book Capitalization PainReform Ltd. (PRFX)|CYTO - Debt to Net Assets Ratio|LIPO: Debts to Book Capitalization|OPTN (OptiNose Inc) - Debts to Book Capitalization|PIRS - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio PROC|Debt to Book Capitalization Ratio PTPI (Petros Pharmaceuticals)|Debt to Book Value qlsyy.net (QLI)|Debts to Book Capitalization SLRN (ACELYRIN)|Debts to Book Capitalization TFF Pharmaceuticals Inc. TFFP